Altria
MO
$71.54
+2.36%
Altria Group, Inc. is a leading tobacco company in the United States, operating primarily through its subsidiaries Philip Morris USA, U.S. Smokeless Tobacco, and John Middleton. The company holds a dominant market position as the leader in cigarettes and smokeless tobacco, with its Marlboro brand commanding a 40% share of the U.S. cigarette market. The current investor narrative centers on the company's high-yield dividend appeal and its challenging transition to smoke-free products, as it navigates declining cigarette volumes through investments in reduced-risk categories like vaping (Njoy), heated tobacco, and nicotine pouches, while also holding significant stakes in Anheuser-Busch InBev and Cronos Group.…
MO
Altria
$71.54
Related headlines
Investment Opinion: Should I buy MO Today?
Rating & Thesis: Hold. Altria is a high-yield, cash-generative defensive stock trading at full valuation after a strong rally; investors should wait for a better entry point. The mixed analyst sentiment, with buys from UBS and Stifel but an underweight from Barclays, reflects this balanced, cautious view.
Supporting Evidence: The stock trades at a forward P/E of 12.80x, a discount to the broader market but arguably fair for a business in secular decline. It offers a high dividend yield of 7.2%, supported by a massive TTM Free Cash Flow of $9.074 billion. However, revenue growth is volatile (Q4 YoY growth of 14.49% is an outlier) and the core business is shrinking. Technically, the stock is overextended, trading at 100% of its 52-week high after a 32.23% six-month surge, leaving little margin of safety.
Risks & Conditions: The two biggest risks are an acceleration in cigarette volume decline eroding cash flow and a dividend cut shattering investor confidence. This Hold rating would upgrade to a Buy if the stock pulls back to the $65-$67 support zone (offering a higher yield and better valuation) or if smoke-free product revenue demonstrates accelerating, sustainable growth. It would downgrade to a Sell if quarterly cigarette shipment declines accelerate beyond mid-single digits or if the payout ratio (currently over 100%) indicates an unsustainable dividend. The stock is currently fairly valued to slightly overvalued relative to its near-term growth prospects and risk profile.
Sign up to view all
MO 12-Month Price Forecast
Altria presents a classic 'wait for a pullback' scenario. The bullish fundamentals—immense cash flow, high yield, and market dominance—are fully priced in after the recent powerful rally. The bearish overhang of secular decline and leverage is persistent. The neutral stance reflects the expectation that the stock will likely churn in a range as the market digests its recent gains and awaits clearer signs of success in the smoke-free transition. The stance would turn bullish on a dip to the mid-$60s, enhancing the yield and margin of safety. It would turn bearish if the stock fails to hold the $67 support level on a closing basis, signaling a breakdown of the current uptrend.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Altria's 12-month outlook, with a consensus price target around $93.00 and implied upside of +30.0% versus the current price.
Average Target
$93.00
6 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
6
covering this stock
Price Range
$57 - $93
Analyst target range
Analyst coverage for Altria is limited, with only 6 analysts providing estimates, indicating it is a well-known but mature stock with less frequent research updates. The consensus sentiment, inferred from recent institutional ratings, is mixed but leans cautiously positive, with firms like UBS and Stifel maintaining 'Buy' ratings while Barclays holds an 'Underweight' and Citigroup a 'Neutral'. The average target price is not explicitly provided in the data, but the estimated EPS average of $6.23 can be used with the forward PE to imply a valuation; however, without a direct consensus price target, the implied upside cannot be precisely calculated. The target range based on estimated EPS is $6.09 (low) to $6.37 (high), which, at a constant forward PE, suggests a narrow price range and reflects low growth expectations. The high target likely assumes successful cost management, stable cigarette pricing power, and incremental progress in reduced-risk products, while the low target prices in accelerated volume declines and regulatory setbacks. The recent pattern of institutional ratings shows stability, with no major downgrades in the provided data from 2025-2026, only a rating initiation to Buy by UBS in January 2026. The relatively small number of analysts and the tight EPS target range suggest a stock where the fundamental story is well-understood, leading to lower forecast dispersion but also potentially less catalyst-driven price movement.
Bulls vs Bears: MO Investment Factors
The bull case for Altria is anchored in its formidable cash generation, defensive high-yield appeal, and undemanding valuation, which have fueled a strong technical breakout. The bear case focuses on the existential threat of secular volume decline in its core business, high financial leverage, and earnings volatility. Currently, the bullish evidence appears stronger, driven by powerful price momentum and the market's reward for its cash returns. The single most important tension in the investment debate is the race between the company's cash-generating engine (funding a 7.2% yield) and the accelerating decline of its cigarette business. The thesis hinges on whether management can successfully deploy that cash to build a sustainable smoke-free future before the core cash cow deteriorates irreversibly.
Bullish
- Exceptional Free Cash Flow Yield: Altria generates immense cash flow, with TTM FCF of $9.074 billion. This supports its high 7.2% dividend yield and provides capital for strategic investments and debt management, making it a compelling income vehicle.
- Strong Momentum & Technical Uptrend: The stock is in a powerful uptrend, up 32.23% over 6 months and 13.85% in the past month, significantly outperforming the S&P 500. It trades at the top of its 52-week range ($74.555), indicating strong investor conviction.
- Undemanding Valuation with Earnings Growth: Altria trades at a trailing P/E of 13.92x and a forward P/E of 12.80x, a discount to the broader market. The recent price rally has been supported by earnings growth, not multiple expansion, as the P/E is below its recent historical level of 21.64x.
- Dominant Market Share & Pricing Power: The company's Marlboro brand commands a 40% share of the U.S. cigarette market. This entrenched position allows for consistent pricing power, which is critical for offsetting the secular decline in cigarette volumes.
Bearish
- Core Business in Secular Decline: Altria's fundamental challenge is the long-term volume decline in its core smokeable products segment, which generated $5.119B of Q4 revenue. The company's future depends on a successful, yet unproven, transition to smoke-free products.
- Highly Leveraged Balance Sheet: The company has a negative debt-to-equity ratio of -7.34 due to negative shareholder equity, indicating significant financial leverage. While supported by strong cash flow, this increases risk in a rising interest rate environment.
- Volatile Quarterly Margins & Earnings: Profitability is inconsistent quarter-to-quarter. Q4 2025 net income ratio was 19.11%, a sharp drop from 45.23% in Q3, and gross margin compressed from 72.58% to 62.11%, indicating potential one-time costs or business pressures.
- Limited Analyst Conviction & Growth: Only 6 analysts cover the stock, and the estimated EPS range is narrow ($6.09 to $6.37), reflecting low growth expectations. The mixed institutional ratings (e.g., Barclays Underweight, Citigroup Neutral) suggest a lack of consensus bullishness.
MO Technical Analysis
The stock is in a sustained uptrend, evidenced by a 1-year price change of +25.70% and a 6-month surge of +32.23%. As of the latest close, the price of $74.55 sits at the very top of its 52-week range (54.7 to 74.555), trading at approximately 100% of the range, which signals strong momentum but also potential overextension and vulnerability to a pullback. Recent momentum has been exceptionally strong, with the stock up 13.85% over the past month and 20.26% over the past three months, significantly outpacing the S&P 500's gains of 9.98% and 4.14% over the same periods, as indicated by positive relative strength figures of +3.87 and +16.12. This acceleration suggests the uptrend is gaining steam, though the proximity to the 52-week high warrants caution for new entries. Key technical levels are clearly defined, with immediate resistance at the 52-week high of $74.555 and support at the 52-week low of $54.7. A decisive breakout above resistance could signal a continuation of the bullish trend, while a failure and reversal would likely target the $65-$67 consolidation zone. The stock exhibits higher volatility than the market, with a beta implied by its price action; its 1-month outperformance of nearly 4 percentage points against the SPY highlights its aggressive recent behavior, which investors must factor into risk management.
Beta
0.52
0.52x market volatility
Max Drawdown
-19.1%
Largest decline past year
52-Week Range
$55-$75
Price range past year
Annual Return
+26.7%
Cumulative gain past year
| Period | MO Return | S&P 500 |
|---|---|---|
| 1m | +7.1% | +8.2% |
| 3m | +6.8% | +9.0% |
| 6m | +22.9% | +10.5% |
| 1y | +26.7% | +26.5% |
| ytd | +24.8% | +8.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MO Fundamental Analysis
Revenue growth is modest but positive, with Q4 2025 revenue of $5.846 billion representing a 14.49% year-over-year increase; however, this strong quarterly growth is partly due to easy comparisons and segment data shows the business remains heavily reliant on Smokeable Products, which contributed $5.119 billion, while Smokeless Products brought in $706 million. The multi-quarter trend shows revenue volatility, with Q3 2025 at $5.251 billion and Q2 at $5.290 billion, indicating underlying business pressures despite the recent pop. The company is highly profitable, with Q4 2025 net income of $1.117 billion and a robust gross margin of 62.11%, though this represents a compression from the 72.58% gross margin reported in Q3 2025. Annual profitability metrics are solid, with a net margin of 34.50% and an operating margin of 74.80%, but the quarterly net income ratio of 19.11% in Q4 is significantly lower than the 45.23% in Q3, pointing to potential margin volatility or one-time impacts. The balance sheet is leveraged, with a negative debt-to-equity ratio of -7.34 due to negative shareholder equity, but the company generates substantial cash flow, with trailing twelve-month free cash flow of $9.074 billion. This strong FCF, which supports the generous dividend, results in a healthy FCF yield, and the current ratio of 0.61 indicates adequate, though not robust, short-term liquidity to meet obligations.
Quarterly Revenue
$5.8B
2025-12
Revenue YoY Growth
+0.14%
YoY Comparison
Gross Margin
+0.62%
Latest Quarter
Free Cash Flow
$9.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MO Overvalued?
Given the positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. Altria trades at a trailing PE of 13.92x and a forward PE of 12.80x based on estimated EPS. The slight discount of the forward multiple suggests the market expects modest earnings growth, but the narrow gap indicates expectations are tempered. Compared to sector averages, Altria's valuation presents a mixed picture; its trailing PE of 13.92x is below the typical market multiple, reflecting the perceived risks associated with the tobacco industry (regulatory, secular decline). However, its Price-to-Sales ratio of 4.80x and EV/EBITDA of 10.89x are key metrics for a cash-generative, defensive business, and they likely trade at a discount to broader consumer staples. The discount is arguably justified by the company's negative long-term volume trends in its core business, despite its high margins and strong cash generation. Historically, the stock's own valuation has fluctuated; the current trailing PE of 13.92x is below the 21.64x reported at the end of Q4 2025, as per historical ratios data, suggesting the recent price rally has been supported by earnings growth rather than multiple expansion. Trading below its recent historical PE band could indicate the market is not yet pricing in excessive optimism, leaving room for multiple normalization if execution on smoke-free transitions improves.
PE
13.9x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -8x~81x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
10.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Altria's primary financial risk is its highly leveraged balance sheet, with a debt-to-equity ratio of -7.34, which could constrain strategic flexibility and amplify losses if cash flow falters. Operationally, the company faces severe margin volatility, as seen in the Q4 2025 gross margin compression from 72.58% to 62.11% and a net income ratio nearly halving from Q3. Furthermore, revenue remains dangerously concentrated, with Smokeable Products comprising 87.5% of Q4 revenue, leaving the company exposed to accelerating volume declines and regulatory shocks in that single segment.
Market & Competitive Risks: The stock's recent surge of 32.23% over six months and trading at its 52-week high creates valuation compression risk, especially if the 'dividend safety' narrative is challenged. Competitively, the transition to reduced-risk products (vaping, heated tobacco) is fraught with execution risk against well-established players, and the company's investments (Njoy, Cronos) have yet to meaningfully offset core declines. Regulatory headwinds, including potential flavor bans and nicotine reduction mandates, pose a persistent threat. The stock's defensive nature is a double-edged sword; in a strong bull market, it may underperform growth sectors, leading to sector rotation risk.
Worst-Case Scenario: The worst-case scenario involves a perfect storm of accelerated cigarette volume decline beyond pricing power offsets, a regulatory crackdown that immediately impacts profitability, and a failure of smoke-free investments to gain traction. This could trigger a dividend cut, leading to a mass exodus of income-focused investors. Quantifying the downside, the stock could realistically retreat to its 52-week low of $54.7, representing a potential loss of approximately -27% from the current price of $74.55. A more severe bear case, incorporating a derating of its P/E multiple, could see losses extend to -35% or more, revisiting the lows seen during prior market crises.
FAQ
The key risks are, in order of severity: 1) Secular Decline Risk: The core cigarette business, which generated 87.5% of Q4 revenue, faces long-term volume erosion that pricing may not fully offset. 2) Financial Leverage Risk: The company's negative debt-to-equity ratio (-7.34) indicates high leverage, increasing vulnerability to rising rates or cash flow disruption. 3) Dividend Sustainability Risk: With a payout ratio over 100%, any significant earnings decline could pressure the cherished 7.2% dividend, triggering a sell-off. 4) Regulatory & Competitive Risk: New regulations on nicotine or flavors, and competition in smoke-free categories, threaten the growth and margin profile of future investments.
The 12-month forecast presents three scenarios. The Base Case (60% probability) sees the stock trading between $70 and $78, as it consolidates recent gains, delivers stable earnings (~$6.23 EPS), and maintains its dividend. The Bull Case (25% probability) targets $79 to $85, driven by successful smoke-free product adoption and P/E expansion. The Bear Case (15% probability) warns of a drop to $55-$65 on accelerated volume declines or dividend fears. The Base Case is most likely, assuming management executes its plan of managed decline and steady investment in alternatives.
MO is fairly valued to slightly overvalued after its recent rally. Its forward P/E of 12.80x is a discount to the broader S&P 500, which is justified given its secular decline and leverage. However, compared to its own recent history—trading below its Q4 2025 P/E of 21.64x—it could be seen as having room for multiple expansion if execution improves. The Price-to-Sales ratio of 4.80x and EV/EBITDA of 10.89x are in line with a mature, cash-generative defensive business. The valuation implies the market expects low single-digit earnings growth, continued dividend payments, and a managed decline of the core franchise.
MO is a good buy for a specific type of investor: one seeking high current income (7.2% yield) from a company with a dominant market position and robust cash flow. However, after a 32% six-month surge to its 52-week high, the near-term risk/reward is balanced, making it less attractive for new money. The stock is fairly valued with a forward P/E of 12.8x. The biggest downside risk is an acceleration in the decline of its core cigarette business. Therefore, it is a good buy for income investors on a meaningful pullback (e.g., towards $65), but a Hold at current levels.
MO is primarily suitable for long-term, income-focused investors with a minimum horizon of 3-5 years. Its high dividend yield is a compounding return engine for a retirement portfolio, but the secular challenges require patience to see if the smoke-free transition succeeds. Its recent high volatility (outperforming SPY by +3.87% in one month) and technical overextension make it a poor candidate for short-term trading, as it is prone to sharp pullbacks. The lack of near-term growth catalysts and the stock's role as a defensive holding further support a long-term, buy-and-hold-for-income strategy.